Unione Europea - croato - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин, metformin hidroklorid - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

Unione Europea - croato - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, бримонидин tartarat - ocular hypertension; glaucoma, open-angle - ophthalmologicals - smanjenje povišenog intraokularnog tlaka (iop) u odraslih bolesnika s otvorenim kutnim glaukom ili očne hipertenzije za koje monoterapija osigurava nedovoljnu redukciju iop.

Unione Europea - croato - EMA (European Medicines Agency)

novartis europharm limited - travoprost - glaucoma, open-angle; ocular hypertension - ophthalmologicals - smanjenje povišenog intraokularnog tlaka kod odraslih bolesnika s okularnom hipertenzijom ili glaukomom otvorenog kuta (vidjeti odjeljak 5. pad od intraokularna veliki pritisak kada pedijatrijska bolesnika u dobi od 2 mjeseca do < 18 godina sa očni hipertenzije ili dijete glaukom (vidi odjeljak 5.

Unione Europea - croato - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

Unione Europea - croato - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastična sredstva - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Bosnia Erzegovina - croato - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amsal pharmaceuticals d.o.o. - Винпоцетин - tableta - 5 mg/1 tableta - jedna tableta sadrži: 5 mg vinpocetina

Bosnia Erzegovina - croato - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amsal pharmaceuticals d.o.o. - Винпоцетин - tableta - 10 mg/1 tableta - jedna tableta sadrži: 10 mg vinpocetina

Croazia - croato - HALMED (Agencija za lijekove i medicinske proizvode)

abbvie d.o.o., strojarska cesta 20, zagreb, hrvatska - neurotoksin clostridium botulinum tip a (900 kda) - prašak za otopinu za injekciju - 4 allergan jedinice/0,1 ml - urbroj: 1 bočica s praškom za otopinu za injekciju sadrži 50 ili 100 allergan jedinica neurotoksina tipa a (iz bakterije clostridium botulinum) nakon rekonstitucije otopina za injekciju sadržava 4 allergan jedinice u 0,1 ml

Unione Europea - croato - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolizam aminokiselina, urođene pogreške - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Unione Europea - croato - EMA (European Medicines Agency)

mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.